Nanatinostat (TFA)

[1]Moffat D, et al. Discovery of 2- (6-{[ (6-fluoroquinolin-2-yl) methyl]amino}bicyclo[3.1.0]hex-3-yl) -N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem. 2010 Dec 23;53 (24) :8663-78.|[2]Smith EM, et al. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway. Oncotarget. 2015 Jul 10;6 (19) :17314-27.|[3]Banerji U, et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18 (9) :2687-94.